FindTrial
Sign In

mFOLFOX-6

DRUG6 trials

Sponsors

Eli Lilly and Company, Georgetown University, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Parabilis Medicines, Inc., Dominik Paul Modest

Conditions

APCAdamantinomatous CraniopharyngiomaAdenomatous Polyposis ColiBeta-cateninCTNNB1CancerColo-rectal CancerColon Cancer

Phase 1

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
CompletedNCT01489865
Georgetown UniversityMetastatic Pancreatic Cancer
Start: 2011-01-03End: 2023-12-07Updated: 2025-11-06
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingNCT05919264
Parabilis Medicines, Inc.Adamantinomatous Craniopharyngioma, Adenomatous Polyposis Coli, APC +17
Start: 2023-05-23End: 2027-08-31Target: 575Updated: 2026-02-10

Phase 2

A Study of Ramucirumab or Icrucumab in Colorectal Cancer
CompletedNCT01111604
Eli Lilly and CompanyColon Cancer, Rectal Cancer
Start: 2010-08-31End: 2013-12-31Updated: 2019-08-06
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
CompletedNCT05268510
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEsophagogastric Adenocarcinoma
Start: 2022-09-15End: 2025-01-09Updated: 2025-02-20
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery
RecruitingNCT05713838
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEsophagus Adenocarcinoma
Start: 2023-08-28End: 2028-12-31Target: 32Updated: 2024-09-19

Phase 3

Pre-Operative Treatment in REseCTable COlon CanceR
Not yet recruitingNCT06899477
Dominik Paul ModestColon Cancer, Colon Carcinoma, Colo-rectal Cancer
Start: 2025-04-30End: 2035-04-30Target: 714Updated: 2025-03-28

Related Papers

PROTECTOR / FIRE‑10: study protocol for a prospective, randomized, open-label, multicenter phase III trial to investigate the efficacy of preoperative systemic therapy in advanced colon cancer
BMC Cancer2026-03-20
CTNI-10. A PHASE 1/2 TRIAL OF FOG-001, A FIRST-IN-CLASS DIRECT β-CATENIN:TCF4 INHIBITOR: SAFETY AND PRELIMINARY ANTITUMOR ACTIVITY IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA (ACP) PATIENTS
Neuro-Oncology2025-11-01
Abstract B031: A phase 1/2 trial of FOG-001, a first-in-class direct β-catenin:TCF4 inhibitor, preliminary safety and efficacy in patients with solid tumors bearing Wnt pathway-activating mutations (WPAM+)
Molecular Cancer Therapeutics2025-10-22
Abstract B141: Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon™) degraders enables pharmacological validation in ERG-fusion prostate cancer models
Molecular Cancer Therapeutics2025-10-22
A phase 1/2 study of FOG-001, a first-in-class direct β-catenin: TCF inhibitor, in patients with colorectal cancer (CRC) and other locally advanced or metastatic solid tumors.
Journal of Clinical Oncology2025-05-28
Abstract 4246: Degradation of the ETS transcription factor ERG by stabilized helical peptide (Helicon™) degraders enables pharmacological validation in ERG-fusion prostate cancer models
Cancer Research2025-04-21
Phase 1/2 study of FOG-001, a first-in-class direct β-catenin:TCF inhibitor, in patients with colorectal cancer, hepatocellular carcinoma, and other locally advanced or metastatic solid tumors.
Journal of Clinical Oncology2025-01-271 citations
A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors.
Journal of Clinical Oncology2024-06-017 citations
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
Journal of Clinical Oncology2024-01-203 citations
Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).
Journal of Clinical Oncology2019-05-2017 citations
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
2016-10-1125 citations